



Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

March 25, 2021

Sent via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: New Drug Introduction Notification pursuant to 18 V.S.A. § 4637(c) and (d)

To the Office of the Attorney General of Vermont.

On March 25, 2021, and pursuant to 18 V.S.A. § 4637(b), BioCryst Pharmaceuticals, Inc. ("BioCryst") provided to the State of Vermont new drug notices for Rapivab® (NDC 72769-0181-03) and Orladeyo™ (NDC 72769-0101-01 and NDC 72769-0102-01).

Pursuant to 18 V.S.A. § 4637(c), and pertaining to both Rapivab and Orladeyo (individually "Product" or together "Products"), BioCryst submits the following additional information:

1. Orladeyo will be promoted as an oral prophylactic to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

Rapivab is promoted for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.


BioCryst currently does not have marketing or pricing plans that are in the public domain. Marketing activities that support the promotion of Orladeyo and Rapivab are designed to increase awareness and understanding with healthcare providers regarding the approved indications, efficacy and safety information that is contained the products approved FDA label.

BioCryst is committed to delivering extraordinary medicines that help patients live ordinary lives and ensuring availability of its products to patients that need them. Our commitment is to do everything in our power to ensure that any patient prescribed our products have access to them. When determining our price, we take into consideration the price of current products in the market with the same indications, as well as the potential value provided to patients, healthcare providers and payors.

2. No information regarding the volume of patients who may be prescribed Orladeyo or Rapivab is in the public domain or publicly available. However, for Orladeyo - Administrative Claims Analysis Estimates US HAE Population at ~10,000 Patients with ~7,500 Diagnosed & Treated. (Data Source: Administrative claims from Symphony Integrated Dataverse (IDV) from 2017-2019 for >270 million US patients). For Rapivab - The CDC estimates that from October 1, 2019, through April 4, 2020, there have been between 410,000 - 740,000 Influenza Hospitalizations.

3. Neither Product received priority review or breakthrough status.

4. BioCryst did not acquire either Product.



If you have any further questions, please do not hesitate to contact me.

Regards,

A handwritten signature in black ink that reads "Joel Turner".

Joel Turner, MBA
Vice President, US Market Access & Patient Services

CELL 918.671-7757

EMAIL jturner@biocryst.com